SIGA TECHNOLOGIES INC
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
PART I-FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited)
PART I - FINANCIAL INFORMATION
Item 1 - Condensed Consolidated Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $171,955,584 | $155,400,262 |
| Accounts receivable | 2,490,234 | 21,166,129 |
| Inventory | 48,006,005 | 49,563,880 |
| Prepaid expenses and other current assets | 5,293,648 | 4,914,613 |
| Total current assets | 227,745,471 | 231,044,884 |
| Property, plant and equipment, net | 1,196,803 | 1,298,423 |
| Deferred tax asset, net | 1,560,453 | 10,854,702 |
| Goodwill | 898,334 | 898,334 |
| Other assets | 202,015 | 240,683 |
| Total assets | $231,603,076 | $244,337,026 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable | $5,032,898 | $1,340,337 |
| Accrued expenses and other current liabilities | 9,472,862 | 5,640,110 |
| Deferred IV TPOXX® revenue | 10,240,000 | 10,330,800 |
| Income tax payable | 96,561 | 8,020,366 |
| Total current liabilities | 24,842,321 | 25,331,613 |
| Other liabilities | 3,281,879 | 3,200,650 |
| Total liabilities | 28,124,200 | 28,532,263 |
| Commitments and contingencies | ||
| Stockholders’ equity | ||
| Common stock ($.0001 par value, 600,000,000 shares authorized, 71,611,302 and 71,404,669, issued and outstanding at September 30, 2025 and December 31, 2024, respectively) | 7,161 | 7,140 |
| Additional paid-in capital | 241,112,674 | 238,635,635 |
| Accumulated deficit | (37,640,959) | (22,838,012) |
| Total stockholders’ equity | 203,478,876 | 215,804,763 |
| Total liabilities and stockholders’ equity | $231,603,076 | $244,337,026 |
The accompanying notes are an integral part of these financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues | ||||
| Product sales and supportive services | $889,748 | $8,942,875 | $85,835,855 | $53,496,869 |
| Research and development | 1,730,252 | 1,066,906 | 4,944,963 | 3,753,658 |
| Total revenues | 2,620,000 | 10,009,781 | 90,780,818 | 57,250,527 |
| Operating expenses | ||||
| Cost of sales and supportive services | 1,002,083 | 1,620,510 | 26,714,283 | 17,157,508 |
| Selling, general and administrative | 4,786,511 | 4,822,591 | 15,949,749 | 18,228,786 |
| Research and development | 7,053,985 | 3,024,593 | 14,914,895 | 8,966,905 |
| Total operating expenses | 12,842,579 | 9,467,694 | 57,578,927 | 44,353,199 |
| Operating (loss)/income | (10,222,579) | 542,087 | 33,201,891 | 12,897,328 |
| Other income, net | 1,866,693 | 1,330,505 | 5,143,981 | 4,590,935 |
| (Loss)/Income before income taxes | (8,355,886) | 1,872,592 | 38,345,872 | 17,488,263 |
| Benefit/(Provision) for income taxes | 1,990,067 | (528,647) | (9,636,811) | (4,034,362) |
| Net and comprehensive (loss)/income | $(6,365,819) | $1,343,945 | $28,709,061 | $13,453,901 |
| Basic (loss)/income per share | $(0.09) | $0.02 | $0.40 | $0.19 |
| Diluted (loss)/income per share | $(0.09) | $0.02 | $0.40 | $0.19 |
| Weighted average shares outstanding: basic | 71,604,956 | 71,368,585 | 71,499,984 | 71,191,019 |
| Weighted average shares outstanding: diluted | 71,604,956 | 71,766,503 | 71,801,188 | 71,853,341 |
The accompanying notes are an integral part of these financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income | $28,709,061 | $13,453,901 |
| Adjustments to reconcile net income to net cash used in operating activities: | ||
| Depreciation and other amortization | 416,089 | 407,692 |
| Stock-based compensation | 2,910,823 | 2,876,071 |
| Write down of inventory, net | 471,971 | 327,373 |
| Deferred income taxes, net | 9,294,249 | (1,056,647) |
| Deferred IV TPOXX® revenue | (90,800) | (7,059,280) |
| Changes in assets and liabilities: | ||
| Accounts receivable | 18,675,895 | 9,041,941 |
| Inventory | 1,085,905 | 2,676,093 |
| Prepaid expenses and other assets | (340,366) | (2,992,590) |
| Accounts payable, accrued expenses and other liabilities | 7,123,239 | (3,659,762) |
| Income tax payable | (7,923,805) | (21,563,085) |
| Net cash provided by/(used in) operating activities | 60,332,261 | (7,548,293) |
| Cash flows from investing activities: | ||
| Capital expenditures | (314,470) | (24,612) |
| Cash used in investing activities | (314,470) | (24,612) |
| Cash flows from financing activities: | ||
| Payment of employee tax obligations for common stock tendered | (433,763) | (638,139) |
| Payment of dividend | (43,028,706) | (42,665,044) |
| Cash used in financing activities | (43,462,469) | (43,303,183) |
| Net increase/(decrease) in cash and cash equivalents | 16,555,322 | (50,876,088) |
| Cash and cash equivalents at the beginning of period | 155,400,262 | 150,145,844 |
| Cash and cash equivalents at end of period | $171,955,584 | $99,269,756 |
| Supplemental disclosure of non-cash financing activities: | ||
| Non-cash lease right-of-use asset and associated liability | $— | $462,686 |
| Issuance of common stock | $— | $417,000 |
The accompanying notes are an integral part of these financial statements
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
1. Condensed Consolidated Financial Statements
The financial statements of SIGA Technologies, Inc. (“we,” “our,” “us,” “SIGA” or the “Company”) are presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission for quarterly reports on Form10-Q and should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended* December 31, 2024*, included in the Company's2024 Annual Report on Form10-K filed on* March 11, 2025 (the "2024 Form10*-K"). All terms used butnot defined elsewhere herein have the meaning ascribed to them in the2024 Form10-K. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results of the interim periods have been included. The2024 year-end condensed consolidated balance sheet data were derived from the audited financial statements but donot include all disclosures required by U.S. GAAP. The results of operations for thethree andnine months ended* September 30, 2025*, arenot necessarily indicative of the results expected for the full year.
2. Summary of Significant Accounting Policies
Revenue Recognition
The Company accounts for revenue in accordance with ASC Topic606, Revenue from Contracts with Customers (“ASC606”). In all transactions, the Company is the principal as it controls the specified good or service before it is transferred to the customer and therefore recognizes revenue on a gross basis. A contract’s transaction price is allocated to distinct performance obligations and recognized as revenue when, or as, a performance obligation is satisfied. As of* September 30, 2025*, the Company's active contractual performance obligations consist of the following: four performance obligations relate to research and development services; andone relates to manufacture and delivery of product. The material performance obligations are referenced in Note3. The aggregate amount of the transaction price allocated to current performance obligations as of* September 30, 2025* was $59.9 million. Current performance obligations represent the transaction price for which work hasnot been performed and excludes unexercised contract options. With respect to current obligations related to the manufacture and delivery of product, the Company expects such obligations to be recognized as revenues within the next 12 months. With respect to the performance obligations related to research and development services, the Company expects such obligations to be recognized as revenue within the nextthree years as the specific timing for satisfying performance obligations is subjective and at times outside the Company's control.
Performance Obligations
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
Contract modifications* mayoccur during the course of performance of our contracts. Contracts are often modified to account for changes in contract specifications or requirements. In most instances, contract modifications are for services that arenot* distinct, and, therefore, are accounted for as part of the existing contract.
The Company’s performance obligations are satisfied over time as work progresses or at a point in time. A portion of the Company's revenue is derived from long-term contracts that span multiple years. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost ofthird-party services performed, cost of direct labor hours incurred, and cost of materials consumed) compared to the total estimated costs to completely satisfy the performance obligation. Incurred costs represent work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer. The incurred and estimated costs used in the measure of progress includethird-party services performed, direct labor hours, and material consumed. The Company accounts for shipping and handling activities as fulfillment costs rather than as an additional promised service.
Contract Balances
The timing of revenue recognition, billings and cash collections* mayresult in billed accounts receivable, unbilled receivables (contract assets) and customer advances and deposits (contract liabilities) in the condensed consolidated balance sheets. Generally, amounts are billed as work progresses in accordance with agreed-upon contractual terms either at periodic intervals (monthly) or upon achievement of contractual milestones; as of September 30, 2025*, the accounts receivable balance in the condensed balance sheet includes approximately $0.2 million of unbilled receivables. Under typical payment terms of fixed price arrangements, the customer pays the Company either performance-based payments or progress payments. For the Company’s cost-type arrangements, the customer generally pays the Company for its actual costs incurred, as well as its allocated overhead and G&A costs. Such payments occur within a short period of time from billing. When the Company receives consideration, or such consideration is unconditionally due, prior to transferring goods or services to the customer under the terms of a sales contract, the Company records deferred revenue, which represents a contract liability.
5
Property, Plant and Equipment
The Company purchased manufacturing equipment duringQ3 2025. Depreciation on the manufacturing equipment will be calculated using the units of production method if and when the Company receives FDA approval for the associated manufacturing site.
Recent Accounting Pronouncements
In* December 2023,the FASB issued ASU2023*-09, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU2023-09 is effective for fiscal years beginning after* December 15, 2024,** maybe applied prospectively or retrospectively, and allows for early adoption. These requirements arenot* expected to have an impact on our consolidated financial statements, but will impact our income tax disclosures.
In* November 2024,the FASB issued ASU2024*-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic220*-40): Disaggregation of Income Statement Expenses*, requiring public entities to disclose additional information about specific expense categories in the notes to the consolidated financial statements on an interim and annual basis. ASU2024-03 is effective for fiscal years beginning after* December 15, 2026,and for interim periods beginning after December 15, 2027,with early adoption permitted. The Company is currently evaluating the impact of adopting ASU2024*-03.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.